mBU/CY

DRUG2 trials

Sponsors

Peking University People's Hospital

Conditions

Leukemia RelapseLeukemia, Myeloid, AcuteRefractory LeukemiaRelapse LeukemiaStem Cell Transplant Complications

Phase 2

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

RecruitingNCT03793517

Peking University People's HospitalLeukemia, Myeloid, Acute, Leukemia Relapse, Stem Cell Transplant Complications

Start: 2018-09-01End: 2026-10-31Target: 55Updated: 2020-03-10

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Peking University People's HospitalRefractory Leukemia, Relapse Leukemia, Stem Cell Transplant Complications

Start: 2018-12-01End: 2023-12-31Target: 55Updated: 2019-05-29

Related Papers

Mega-Dose Decitabine Intensified Regimen Is More Effective at Eliminating Pre-HSCT Measurable Residual Disease Compared to the Bu/Cy Regimen: A Multicenter Prospective Phase II Study

Blood2023-11-021 citations